Scholarlink

<p>Suzetrigine (JOURNAVX<sup>™</sup>), a first-in-class voltage-gated sodium channel&#xa0;1.8 (Na<sub>V</sub>1.8) inhibitor, is an efficacious and well-tolerated non-opioid analgesic approved in the USA for the treatment of moderate to severe acute pain in adults. By selectively inhibiting the peripherally restricted Na<sub>V</sub>1.8 to reduce pain signal transmission, suzetrigine is expected to have minimal addictive potential. As shown in two double-blind, placebo- and active-controlled phase&#xa0;3 trials in adults experiencing moderate to severe acute pain following a bunionectomy or abdominoplasty, a 48-h course of oral suzetrigine reduces pain intensity significantly more than placebo, although the trials did not demonstrate the superiority of suzetrigine over the opioid-based active comparator, hydrocodone bitartrate/acetaminophen 5&#xa0;mg/325&#xa0;mg. Suzetrigine is generally well tolerated; in clinical trials, nausea, constipation, and headache were the most common adverse events and most were of mild or moderate severity. No evidence of addictive potential for suzetrigine was found based on in vitro, preclinical, and clinical trial data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Suzetrigine in moderate to severe acute pain: a profile of its use

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Aisling McGuigan,
  • Matt Shirley

摘要

Suzetrigine (JOURNAVX™), a first-in-class voltage-gated sodium channel 1.8 (NaV1.8) inhibitor, is an efficacious and well-tolerated non-opioid analgesic approved in the USA for the treatment of moderate to severe acute pain in adults. By selectively inhibiting the peripherally restricted NaV1.8 to reduce pain signal transmission, suzetrigine is expected to have minimal addictive potential. As shown in two double-blind, placebo- and active-controlled phase 3 trials in adults experiencing moderate to severe acute pain following a bunionectomy or abdominoplasty, a 48-h course of oral suzetrigine reduces pain intensity significantly more than placebo, although the trials did not demonstrate the superiority of suzetrigine over the opioid-based active comparator, hydrocodone bitartrate/acetaminophen 5 mg/325 mg. Suzetrigine is generally well tolerated; in clinical trials, nausea, constipation, and headache were the most common adverse events and most were of mild or moderate severity. No evidence of addictive potential for suzetrigine was found based on in vitro, preclinical, and clinical trial data.